Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Long-Term Investments (2025)

NewAmsterdam Pharma (NAMS) has disclosed Long-Term Investments for 1 consecutive years, with $92.6 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments changed N/A to $92.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $92.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $92.6 million for FY2025, N/A changed from the prior year.
  • Long-Term Investments hit $92.6 million in Q4 2025 for NewAmsterdam Pharma, up from $53.1 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $92.6 million in Q4 2025 to a low of $44.2 million in Q2 2025.